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Abstract 22 
The deleterious role of chronic activation of the IL-1β system in type 2 diabetes and other 23 
metabolic diseases is well documented. However, a possible physiological role of IL-1β in 24 
glucose metabolism remained unexplored. Here we show that feeding induces a 25 
physiological increase in the number of peritoneal macrophages, which secrete IL-1β in a 26 
glucose-dependent manner. Subsequently, IL-1β contributes to postprandial stimulation of 27 
insulin secretion. Accordingly, lack of endogenous IL-1β in mice during refeeding and obesity 28 
reduced plasma insulin. IL-1β and insulin increased glucose uptake into macrophages, and 29 
insulin reinforced a pro-inflammatory pattern via the insulin receptor, glucose metabolism, 30 
reactive oxygen species production, and NLRP3 inflammasome-mediated IL-1β secretion. 31 
Post-prandial inflammation is limited by normalization of glycemia and can be prevented by 32 
inhibition of sodium-glucose cotransporter 2 (SGLT2). Our findings identify a physiological 33 
role for IL-1β and insulin in the regulation of both metabolism and immunity.  34 
  35 
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Introduction 36 
Activation of the innate immune system is an initial response of the body to infections and 37 
injuries. The resulting inflammation aims at protecting against stressors and at restoring 38 
tissue and organism homeostasis. This process is largely driven by IL-1β, one of the first 39 
described cytokines1. However, prolonged activation of the immune system by over-40 
nutrition may eventually promote the development of metabolic diseases2-6. A critical sensor 41 
of nutrient overload is the NLRP3 inflammasome, which processes pro-IL-1β to its active 42 
form in various metabolic disorders. This is the case for uric acid crystals which activate the 43 
NLRP3 inflammasome in gout7, for cholesterol crystals in atherogenesis8, and for glucose, 44 
fatty acids and islet amyloid polypeptide in type 2 diabetes9-13. Importantly, a causal link 45 
between IL-1β-induced inflammation and these metabolic diseases has been demonstrated 46 
by various genetic and pharmacological approaches in animal models14-16 and in clinical 47 
trials17-21. While these studies shed light on the pathological role of IL-1β in metabolism, a 48 
physiological function of IL-1β in metabolic control remains largely unexplored.  49 
 50 
In response to pathogens and obesity, profound changes in the metabolism of immune cells 51 
take place22-25. Beyond supplying energy, nutrients can also act as signaling molecules that 52 
promote the activation of immune cells. Indeed, elevated glucose and other metabolites 53 
drive production of IL-1β by macrophages14,26.  54 
 55 
Insulin-producing β cells have the highest IL-1 receptor expression of any tissue27 and the IL-56 
1 receptor is the most abundantly expressed cell surface receptor on β cells28, pointing to a 57 
hitherto unappreciated physiological function. While the deleterious role of high-dose and 58 
long-term IL-1β exposure on islet function and mass is well documented29,30, a few mainly in 59 
vitro observations hint to a possible beneficial role of IL-1β in insulin secretion and β-cell 60 
survival31,32.  61 
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 62 
Parenteral glucose stimulation leads to a rapid first and second phase of insulin release. In 63 
contrast, the physiological slower resorption of a meal elicits a sustained increase of insulin 64 
that depends on the duration of food intake33. Thereby the insulin response to enteral food 65 
intake cannot be solely accounted for by the associated changes in blood glucose. It is 66 
modulated by several insulin secretagogues including the incretin hormones GIP and GLP-67 
134. These hormones promote insulin secretion only when glucose levels are elevated. While 68 
GIP and GLP-1 are the best described incretins, other incretin-like factors are thought to 69 
exist. 70 
 71 
Several studies show that food intake transiently induces a mild inflammatory response35,36. 72 
We hypothesized that IL-1β contributes to this postprandial inflammation, regulating whole 73 
body glucose homeostasis along with an innate immune response. Thereby, it may deliver 74 
the energy needed to activate the innate immune system in order to prevent the 75 
dissemination of microorganisms contained in the food. We show here that a postprandial 76 
rise in glucose leads to acute elevation of macrophage-derived IL-1β, which contributes to 77 
postprandial insulin secretion via the abundantly expressed IL-1 receptor on β cells. Insulin 78 
reinforces a pro-inflammatory state and stimulates macrophages to produce IL-1β via 79 
glucose metabolism, subsequent production of reactive oxygen species (ROS) which leads to 80 
activation of the inflammasome14,37. Both, insulin and IL-1β regulate glucose disposal, 81 
whereby IL-1β preferentially stimulates glucose uptake into the immune cell compartment.  82 
  83 
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Results 84 
 85 
Feeding stimulates intra-peritoneal macrophages to produce IL-1β. 86 
In order to study the physiological involvement of IL-1β in insulin secretion we performed 87 
overnight fasting followed by refeeding experiments in wild-type and IL1b-/- mice. Two hours 88 
after refeeding, circulating IL-1β concentration was increased in wild-type mice, while, as 89 
expected, IL-1β remained undetectable in IL1b-/- mice (Fig. 1a; for validation of the assay see 90 
Supplementary Fig. 1a). Of note, IL-1β concentration in serum was already elevated 30 91 
minutes after refeeding (not shown). Next we investigated the source of increased IL-1β. 92 
Following refeeding, expression of Il1b mRNA and of the IL-1β-dependent chemokines Cxcl1 93 
and Ccl2 were increased in the omental fat (the main site from which macrophages migrate 94 
into the peritoneum38,39; Fig. 1b) but not in the circulating leukocytes, liver, spleen, 95 
epididymal fat or subcutaneous fat (not shown). Furthermore, the number of stromal 96 
vascular cells isolated from the omentum was reduced (fasted: 41.8 ± 13.4 x 103 cells/mg; 97 
refed: 8.3 ± 2.6 x 103 cells/mg; mean ± s.e.m.). Accordingly, we observed a marked increase 98 
in the number of peritoneal cells (Fig. 1c), which displayed an increase in Il1b mRNA 99 
expression (Fig. 1d). Flow cytometry revealed that the majority of these cells were 100 
macrophages (Fig. 1e; for gating strategy see Supplementary Fig. 1b), a repartition that 101 
remained unchanged between fasting and refeeding (not shown). Ex vivo, spontaneous 102 
release of IL-1β by cultured peritoneal macrophages from fasted or refed mice was 103 
comparable (not shown). However, macrophages from refed mice released more IL-1β 104 
following stimulation with ATP (Fig. 1f). To validate the source of the increased IL-1β during 105 
refeeding, we generated Il1bfl/flLyz2-Cre mice, which specifically lack IL-1β in the myeloid 106 
lineage (Supplementary fig. 1c). Two hours after refeeding, circulating IL-1β concentration 107 
was increased in wild-type mice but not in their Il1bfl/flLyz2-Cre littermates (Fig 1g). We then 108 
tested whether the increase in serum glucose following feeding mediated the postprandial 109 
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increase in IL-1β. We treated mice with the SGLT2 inhibitor canagliflozin, which decreases 110 
glycemia via inhibition of renal glucose reabsorption. Treatment of mice with canagliflozin 111 
induced glycosuria and prevented postprandial increase in glucose and insulin 112 
(Supplementary Fig. 1d-f), along with a complete prevention of postprandial increase in 113 
circulating IL-1β (Fig. 1h). Similarly, injection of the non-metabolizable glucose analogue 2-114 
deoxyglucose (2DG) prior to refeeding strongly reduced IL-1β release (Fig. 1i). Finally, we 115 
tested the role of bacterial products in the stimulation of postprandial IL-1β by treating mice 116 
with broad-spectrum antibiotics or lipopolysaccharide (LPS). Antibiotics-treated mice tended 117 
to have milder postprandial inflammation than untreated mice as detected by Il1b and Cxcl1 118 
gene expression in the omental fat pad (Supplementary Fig. 1g, h) together with a mild 119 
decrease in postprandial circulating IL-1β (Supplementary Fig. 1i) despite similar food intake 120 
and no change in the number of peritoneal cells (Supplementary Fig. 1j-l). Ex vivo, 121 
peritoneal macrophages from antibiotic-treated mice released less IL-1β, even in the 122 
presence of ATP (Fig. 1j). However, priming with LPS prior to ATP stimulation restored IL-1β 123 
secretion (Fig. 1j). Accordingly, in vivo i.p. injection of LPS into fed mice increased circulating 124 
IL-1β along with insulin and decreased blood glucose (Fig. 1k). However, injection of LPS in 125 
genomic Il1b–/– mice failed to induce insulin (Fig. 1l). This suggests that there is a need for a 126 
microbial-related stimulus and energy supply (glucose) to induce postprandial release of IL-127 
1β. Thus, feeding increases the number of intra-peritoneal macrophages, which are primed 128 
by bacterial products to produce and release IL-1β in response to glucose. 129 
 130 
Postprandial macrophage IL-1β promotes insulin secretion. 131 
Next, we examined the direct effect of elevated IL-1β after refeeding on insulin secretion. 132 
First, we measured postprandial circulating insulin in littermate Il1b-/- or wild-type refed 133 
mice. Il1b-/- mice had reduced insulin secretion (Fig. 2a) and elevated blood glucose 134 
(Supplementary Fig. 2a) after refeeding compared to wild-type mice, despite comparable 135 
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food intake (not shown). Since the number of peritoneal cells was increased upon refeeding 136 
(Fig. 1c), and macrophages are the most abundant immune cells in the peritoneal cavity (Fig. 137 
1e), we depleted macrophages in wild-type mice by i.p. injection of clodronate 138 
(Supplementary Fig. 2b) prior to performing fasting-refeeding experiments. Depletion of 139 
macrophages resulted in a marked decreased of postprandial insulin in the circulation (Fig. 140 
2b). Similarly, postprandial insulin was lower in Il1bfl/flLyz2-Cre mice compared to their wild-141 
type littermates (Fig. 2c). In addition, acute blockade of IL-1 with its natural antagonist IL-142 
1Ra prior to refeeding resulted in slightly decreased circulating insulin in wild-type mice (Fig. 143 
2d) and elevated blood glucose (Supplementary Fig. 2c). Since obesity is associated with 144 
inflammation and chronically elevated IL-1β and insulin9, we investigated the effect of acute 145 
(1 hour before refeeding) IL-1 antagonism in diet- induced obese (DIO) mice to substantiate 146 
the ability of endogenous IL-1β to regulate insulin. Blocking the elevated circulating levels of 147 
IL-1β (Fig. 2e) with IL-1Ra lowered fasting insulin levels in DIO mice (Fig. 2f) without 148 
changing insulin sensitivity or hepatic glucose production as determined by a 149 
hyperinsulinemic-euglycemic clamp (Fig. 2g, h). As a second model, genetically obese db/db 150 
mice were injected with IL-1Ra, which also decreased insulin levels (Fig. 2i). Therefore, 151 
postprandial IL-1β derived from myeloid cells promotes insulin secretion.  152 
 153 
Acute exposure to IL-1β induces insulin secretion. 154 
To directly test the effect of IL-1β on insulin secretion in vivo, we performed acute injections 155 
of IL-1β in mice followed by i.p. glucose tolerance test (GTT). IL-1β led to a marked elevation 156 
in insulin secretion (Fig. 3a) and improved glucose tolerance (Fig. 3b). Insulin was also 157 
increased and glycemia improved by IL-1β administration in the absence of a glucose bolus 158 
but to a much lesser extent (Fig. 3c, d; note the different scale in the y-axis compared to 3a 159 
& b). This glucose-dependent potentiation of insulin secretion is reminiscent of effects 160 
elicited by the incretin hormones GLP-1 and GIP34. However, circulating active GLP-1 161 
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concentrations remained unchanged following IL-1β injections (Supplementary Fig. 3a). 162 
Furthermore, the effect of IL-1β on insulin secretion and glucose tolerance was identical in 163 
Glp1r-/-/Gipr-/- double knock-out mice compared to their wild-type littermates 164 
(Supplementary Fig. 3b, c) and treatment of mice with the GLP-1 inhibitor Exendin fragment 165 
9-39 did not reduce the IL-1β effect on insulin secretion (not shown). Therefore, IL-1β did 166 
not promote glucose-induced insulin secretion via incretin hormones. Since insulin secretion 167 
could be increased as a result of IL-1β-mediated peripheral insulin resistance, we 168 
determined if insulin sensitivity changes upon an acute IL-1β injection using insulin tolerance 169 
tests and hyperinsulinemic-euglycemic clamp studies. Acute injection of IL-1β had no effect 170 
on insulin sensitivity or hepatic glucose production (Fig. 3e, Supplementary Fig. 3d). IL-1β 171 
also improved glucose tolerance and strongly increased insulin secretion in DIO mice (Fig. 3f, 172 
g) and in genetically obese db/db mice (Fig. 3h, i). In contrast to wild-type mice, interleukin 1 173 
receptor-associated kinase 4 (Irak4-/-) deficient mice injected with IL-1β before an i.p. GTT 174 
showed no improvement in insulin secretion and no change in glycemia (Supplementary Fig. 175 
3e, f) demonstrating that the observed effects of IL-1β are mediated by the IL-1 receptor 176 
signal transduction pathways. Of note, i.p. injection of 0.1 μg/kg of IL-1β resulted in 177 
circulating IL-1β concentrations similar to those obtained upon refeeding and also induced 178 
insulin secretion (Fig. 3j, k). Next we tested whether LPS has similar effects. Acute i.p. LPS 179 
injection improved glucose tolerance and increased insulin secretion in both wild-type and 180 
DIO mice (Fig. 4a, b). Importantly, IL-1Ra treatment blocked LPS-induced insulin secretion 181 
(Fig. 4c). Type 1 IL-1 receptor mRNA (Il1r1) was expressed at a much higher level in isolated 182 
endocrine cells than in islet resident immune or endothelial cells (Fig. 4d). Specific 183 
immunostaining of mouse pancreatic tissue sections revealed the presence of IL-1R1 in a 184 
subpopulation of β cells (Fig. 4e). Previous in vitro studies32 demonstrated that very low 185 
concentrations of IL-1β increased glucose-stimulated insulin secretion from islets. We 186 
confirmed this effect in mouse and human islets, and with the human β-cell line ENDOC 187 
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(Supplementary Fig. 3g-i), suggesting a direct β-cell effect. To determine whether acute 188 
administration of IL-1β, in vivo, acts directly on the islet, we used streptozotocin (STZ) to 189 
eliminate β cells from recipient mice and transplanted them with islets from wild-type or 190 
Il1r1–/– donor mice. The effect of IL-1β on insulin secretion and glucose tolerance was lost in 191 
Il1r1–/– transplanted mice (Fig. 4f, g). These results suggest that systemic IL-1β potentiates 192 
glucose-induced insulin secretion via islet IL-1R1, and this is independent of the incretins 193 
GLP-1 and GIP or of changes in insulin resistance. 194 
 195 
Insulin stimulates IL-1β secretion of macrophages  196 
Since IL-1β enhanced insulin secretion during refeeding, we investigated the possible 197 
synergistic contribution of insulin and IL-1β to the stimulation of the immune system. First 198 
we investigated by flow cytometry the expression of the insulin receptor (InsR) on resident 199 
macrophages isolated from several tissues. We found that peritoneal macrophages had the 200 
highest insulin receptor expression compared to other resident macrophages (Fig 5a). 201 
Moreover, we found that the InsR was upregulated in peritoneal macrophages from DIO 202 
mice (Fig. 5b) and in the pro-inflammatory M1 compared to naive M0 macrophages, 203 
whereas it was mildly downregulated in anti-inflammatory M2 macrophages (Fig. 5c, 204 
Supplementary Fig. 4a). Accordingly, insulin induced AKT phosphorylation in naive M0, to a 205 
greater extent in M1 and not in M2 macrophages (Fig. 5d, Supplementary Fig.4b). The 206 
insulin effect on AKT phosphorylation was confirmed using a quantitative multiplex assay 207 
(Fig. 5e). In contrast to the PI3K activation pathway, insulin had no impact on MAPK 208 
signaling (Fig. 5f). Insulin also stimulated upregulation of the glucose transporter Slc2a1 209 
(encodes GLUT1, the isoform that is mainly expressed in immune cells25; Fig. 5g) and the 210 
expression of hexokinase 2 (Hk2), the rate-limiting enzyme in glycolysis (Fig. 5h), in M1 211 
macrophages. In line with this pattern, a 2 hour insulin treatment increased glycolytic 212 
activity in M1 macrophages, but not in naive or M2 macrophages (Fig. 5i, Supplementary 213 
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Fig. 4c). In accordance with the phosphorylation assay, the AKT signaling inhibitor LY294002 214 
but not the MAPK signaling inhibitor U0126 blocked the effect of insulin on glycolytic activity 215 
in M1 macrophages (Fig. 5j). Further, insulin induced glucose uptake in naive macrophages, 216 
and this effect was enhanced by IL-1β (Fig 5k). Similar to the pattern of insulin receptor 217 
expression and activation, insulin induced secretion of mature IL-1β preferentially in M1 218 
macrophages in an NLRP3-dependent manner (Fig. 6a). Insulin also stimulated Tnf, Il6, and 219 
Cxcl1 expression and protein release in M1 macrophages but independently of NLRP3 220 
activation (Supplementary Fig. 4d, e). This insulin effect on IL-1β appeared to be 221 
independent of cell death and survival, which remained unaffected (Supplementary Fig. 4f). 222 
Similar to insulin-induced glycolysis, insulin stimulated IL-1β via the PI(3)K activation 223 
pathway and was blocked by LY294002 and downstream by the mTOR inhibitor rapamycin 224 
(Fig. 6b). We then tested the role of glucose metabolism in insulin-induced IL-1β secretion. 225 
First, the GLUT1 inhibitor fasentin blocked IL-1β secretion (Fig. 6c). In addition, insulin failed 226 
to induce IL-1β when cells were cultured with the non-metabolizable glucose analogue 2DG 227 
or with the mitochondria targeted ROS scavenger Mito-TEMPO (Fig. 6d). IL-1Ra was 228 
undetectable following short-term exposure (2 hours) to insulin (not shown) however 229 
prolonged (12 hours) exposure to insulin induced IL-1Ra in M0 and M1 macrophages 230 
indicating that the induction of IL-1β was later counterbalanced by IL-1Ra secretion (Fig. 6e, 231 
f). Similarly to our in vitro data, acute injection of insulin in mice increased amounts of 232 
circulating IL-1β and CXCL1 (Fig. 6g, Supplementary Fig. 4g). Overall, these data show that 233 
insulin induces inflammasome-mediated IL-1β secretion via enhanced glucose metabolism 234 
and mitochondrial ROS production. These effects are dependent on the AKT/-PI(3)K pathway 235 
and on the activity status of the macrophages. 236 
 237 
IL-1β shifts glucose uptake to immune cells 238 
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Next, we tested how IL-1β contributes to glucose disposal. Exposure of macrophages to IL-239 
1β led to an increase in glucose uptake (Fig. 7a), while blocking endogenously produced IL-1 240 
with IL-1Ra slightly decreased glucose uptake (Fig. 7b). We then examined the effect of IL-1β 241 
and insulin injection on glucose uptake in wild-type mice. To avoid glucose-stimulated 242 
insulin secretion, we only used trace amounts of non-metabolizable radiolabeled glucose. IL-243 
1β stimulated glucose uptake in spleen and circulating leukocytes (Fig. 7c, d). IL-1β also 244 
increased glucose uptake in adipose tissue and in muscle, however to a lesser extent than 245 
insulin (Fig. 7e-g). This is potentially due to the mild stimulation of insulin secretion by IL-1β 246 
observed in the absence of a glucose bolus (Fig. 3c). To mimic the chronic elevation of IL-1β, 247 
we injected mice with IL-1β daily for 3 consecutive days and determined the number and 248 
glucose uptake of peritoneal cells. Similar to refed mice, IL-1β-injected mice had more 249 
peritoneal cells (Fig. 7h). Ex vivo, glucose uptake of macrophages from these mice was 250 
increased (Fig. 7i). To test the physiological relevance of IL-1β-induced glucose uptake, we 251 
investigated postprandial glucose uptake in immune cells of refed mice. Blockade of 252 
endogenous IL-1 with IL-1Ra decreased glucose uptake in peritoneal macrophages (Fig. 7j). 253 
To further examine the contribution of immune cells to overall body glucose disposal, we 254 
first used T and B cell deficient (Rag2-/-) mice. A single injection of IL-1β prior to a GTT in 255 
Rag2-/- mice lowered glucose concentration as potently as in littermate control mice 256 
(Supplementary Fig. 5a). Since Rag2-/- mice have a compensatory increase in the number of 257 
macrophages, we additionally ablated macrophages in Rag2-/- mice with clodronate 258 
liposomes (Supplementary Fig. 5b). This diminished the profound beneficial effect of IL-1β 259 
on glucose disposal, despite increased insulin levels (Fig. 7k), suggesting that immune cells 260 
substantially contribute to IL-1β-induced glucose disposal. Thus, beside the stimulation of 261 
insulin, IL-1β directly regulates glycemia by promotion of glucose disposal preferentially in 262 
immune cells (Supplementary Fig. 6).  263 
  264 
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Discussion 265 
In the present study we show that feeding induces a physiological elevation of macrophage-266 
derived IL-1β that promotes postprandial insulin secretion. This effect depends on bacterial 267 
products, which primes macrophages to produce more pro-IL-1β, and on glucose that drives 268 
the maturation of IL-1β. The production of IL-1β by M1, and to a lesser extent by M0, 269 
macrophages is enhanced by insulin. Insulin upregulates functional insulin receptors, 270 
signaling via the AKT/-PI(3)K pathway, glucose uptake through the glucose transporter 271 
GLUT1, glucose metabolism, and ROS production that activates the NLRP3 272 
inflammasome14,37. Both insulin and IL-1β regulate whole body glucose disposal by 273 
promoting glucose uptake in muscle and fat, and fuel the immune system by stimulating 274 
glucose uptake into the immune cell compartment. Ablation of macrophages in T- and B-cell 275 
deficient mice significantly reduced IL-1β-mediated glucose clearance. Self-amplification of 276 
the system is limited by normalization of glycemia. 277 
 278 
The number of macrophages in the peritoneum was increased upon refeeding along with 279 
increased expression of inflammatory genes including Il1b in omental fat, which supports 280 
active trafficking of macrophages into the peritoneal cavity40. Therefore, feeding stimulates 281 
immune surveillance, possibly to limit the dissemination of microorganisms contained in 282 
food. Activation of the immune system requires energy and contributes substantially to 283 
whole-body glucose consumption. We provide evidence that both, bacterial products and 284 
glucose metabolism, are required to induce postprandial IL-1β secretion by peritoneal 285 
macrophages. Indeed, we show that peritoneal cells from refed mice have elevated Il1b 286 
mRNA levels. This might rather be promoted by translocation of ingested or intestinal 287 
bacterial products than by the microbiota itself41-43, since pretreatment of mice with 288 
antibiotics before refeeding only mildly lowered IL-1β secretion. However, stimulation of IL-289 
1β release strongly depends on glucose uptake and metabolism. Indeed, we observed that 290 
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decreasing glycemia via SGLT2 inhibition or blocking glycolysis with 2DG prevented 291 
postprandial IL-1β in the circulation. This suggests that from all factors that could mediate 292 
this effect during feeding, such as mechanical stress of the digestive system, fiber, amino 293 
acid and fat intake, it is mainly glucose that drives IL-1β secretion. Our results also suggest a 294 
role for insulin in postprandial IL-1β secretion since insulin increased glucose uptake and 295 
metabolism in macrophages. Inhibition of glucose uptake with fasentin or 2DG blocked 296 
insulin-induced IL-1β secretion. Downstream, inhibiting mitochondrial ROS production, 297 
which activates the NLRP3 inflammasome14,37, also prevented insulin from inducing IL-1β. 298 
 299 
Previous in vitro studies have shown that low concentrations of IL-1β mildly stimulate insulin 300 
secretion32. Here we show that in vivo, IL-1β injections strongly potentiate insulin secretion 301 
in the presence of a glucose bolus. However, the most natural way to stimulate insulin 302 
secretion is eating. We find that IL-1β-induced insulin release occurs in physiology by 303 
demonstrating that postprandially produced IL-1β increased insulin levels and decreased 304 
glycemia. This IL-1β effect is partly mediated by the highly expressed IL-1R1 on β-cells, since 305 
the effect of IL-1β on insulin secretion and glucose tolerance was blunted in diabetic mice 306 
transplanted with islets from Il1r1–/– mice.  307 
 308 
The beneficial effects of postprandial IL-1β on glucose homeostasis are in apparent contrast 309 
to the glucose lowering effects of IL-1 antagonism in patients with type 2 diabetes17 and to 310 
the well-described deleterious effects of IL-1β on islet function and survival4. Though IL-1β 311 
provokes β-cell demise30,44, at low concentrations or upon short exposure, IL-1β 312 
paradoxically stimulates β-cell proliferation and decreases apoptosis32. Therefore, IL-1β is 313 
not only detrimental for β-cells but has more complex biological functions45. An explanation 314 
to reconcile the beneficial effects of IL-1 blockade in type 2 diabetes is the difference 315 
between acute and chronic effects and the concept of β-cell “rest”. Indeed, potassium 316 
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channel openers, which decrease insulin secretion, ultimately improve insulin secretion in 317 
patients with type 2 diabetes46. The benefit of IL-1 antagonism in patients with type 2 318 
diabetes could result from β-cell rest, possibly in combination with inhibition of the toxic 319 
effects of IL-1β.  320 
 321 
A further explanation why chronic upregulation of IL-1β leading to elevated insulin levels 322 
may become unfavorable for metabolism stems from our observation that insulin reinforces 323 
the inflammatory state of macrophages through enhanced glucose uptake and metabolism 324 
and increased InsR expression in macrophages of DIO mice. Indeed, activated macrophages 325 
play a crucial role in insulin resistance47. In line with this, insulin receptor expression was 326 
also higher in macrophages from DIO mice, where macrophages have been shown to be pro-327 
inflammatory6. Thus, we propose that insulin, which is increased in early stages of type 2 328 
diabetes, may drive and sustain the inflammatory state in macrophages and may therefore 329 
contribute to the chronic low-grade inflammation associated with metabolic diseases. 330 
Thereby, TNFα, IL-6 and CXCL1 may also add to the effect of IL-1β. In support, myeloid cell-331 
restricted InsR deficient mice are protected against metabolic inflammation and insulin 332 
resistance48. 333 
 334 
The effect of insulin in macrophages was previously studied without taking into account the 335 
polarization status of the macrophages 49. Herein we show that insulin preferentially acts on 336 
pro-inflammatory M1 macrophages characterised by more InsRs, enhanced downstream 337 
AKT phosphorylation and glycolytic activity. Further insulin promotes the NLRP3 338 
inflammasome and leads to macrophage-derived IL-1β release. Interestingly, peritoneal 339 
macrophages had the highest insulin receptor density, supporting their contribution to 340 
postprandial homeostasis. 341 
 342 
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SGLT2 inhibitors have recently been approved for the treatment of type 2 diabetes and the 343 
EMPA-REG outcome study revealed an impressive reduction in mortality50. However the 344 
mechanisms leading to this protective effect are unclear. In the present study, we show that 345 
canagliflozin prevents postprandial IL-1β elevation in the circulation. This could be due to 346 
increased glucose excretion in the urine, which prevents an overload of glucose in tissues, 347 
thereby avoiding deleterious chronic effects of glucose-induced IL-1β.  348 
 349 
Altogether, our findings show that IL-1β, a master regulator of inflammation, and insulin, a 350 
key hormone in glucose metabolism, promote each other. Both have potent effects on 351 
glucose homeostasis and on the activity of the immune system, supporting the emerging 352 
concept that inflammatory mediators play a role not only in the pathology of metabolism 353 
but are an integral part of its physiology. The physiological synergy between IL-1β and 354 
insulin on glucose disposal may be required to cope with the concomitant challenge by 355 
nutrients and microorganisms related to food intake.  356 
  357 
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Figure legends 512 
 513 
Figure 1 514 
Feeding stimulates intra-peritoneal macrophages to produce IL-1β. 515 
(a) Circulating IL-1β in wild-type (WT; n=22, 4 experiments) or Il1b–/– (n=3) mice before and 516 
after feeding (LLOD denotes the lowest level of detection). (b) Gene expression in omental 517 
fat isolated from fasted and refed mice (n=8, 3 experiments). (c) Number of peritoneal cells 518 
isolated per mouse (WT, fasted n=15 and refed n=17, 4 experiments). (d) Il1b gene 519 
expression in peritoneal cells isolated from fasted and refed mice (n=6). (e) Peritoneal cell 520 
composition following feeding determined by flow cytometry (pool of 4 refed mice). (f) IL-1β 521 
release of macrophages isolated from fasted (n=5) or refed (n=6) mice and stimulated with 522 
ATP. (g-i) Circulating IL-1β levels before (fasted) or after refeeding (refed) in Il1bfl/flLyz2-Cre 523 
and WT mice (g; n=16 and 15, respectively), in mice treated with or without the SGLT2 524 
inhibitor canagliflozin (h; n=13 per group), and in mice treated with or without 2DG (i; saline 525 
n=9, 2DG n=10). (j) Ex vivo IL-1β secretion in unstimulated (basal) macrophages isolated 526 
from refed mice pretreated for a week with or without antibiotics (ABX, left) or stimulated 527 
with ATP (middle) alone or following LPS priming (right). (k) Circulating IL-1β, insulin, and 528 
blood glucose levels after intra-peritoneal (i.p.) injection of LPS (1 mg/kg) in fed mice (n=8). 529 
(l) Circulating insulin levels in fed WT or Il1b–/– mice after i.p. injection of 1 mg/kg LPS or 530 
saline (WT; saline n=5, LPS n=7, Il1b–/–; n=7). *P < 0.05, **P < 0.01, ***P<0.001, ****P < 531 
0.0001. Statistical significance (P) was determined by Student's t test and in (b, g, h, I) by 532 
ANOVA. All error bars denote s.e.m.  533 
 534 
Figure 2 535 
Postprandial macrophage-derived IL-1β promotes insulin secretion. 536 
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(a) Circulating insulin concentration before (fasted) or after refeeding (refed) in Il1b-/- or WT 537 
mice (n=6 and 11, respectively). (b, c) Circulating insulin before (fasted) or after refeeding 538 
(refed) in (b) WT mice injected with liposomes containing clodronate or PBS (n=17 per 539 
group; 3 experiments), and in (c) Il1bfl/flLyz2-Cre (n=16) and WT (n=15) mice. (d) Circulating 540 
insulin following an acute injection of saline or 10 mg/kg IL-1Ra in refed WT mice (n=26 and 541 
23, respectively). (e) Basal circulating IL-1β levels in control (n=8) or DIO (n=10) mice. (f) 542 
Circulating insulin following acute injections of saline or 10 mg/kg IL-1Ra in DIO mice (n=15 543 
and 13 respectively). Hyperinsulinemic-euglycemic clamp in DIO mice pre-injected with 544 
saline or with 10 mg/kg IL-1Ra (n=4 and 5, respectively): (g) Glucose infusion rate, (h) hepatic 545 
glucose production. (i) Circulating insulin levels following acute injections of saline or 10 546 
mg/kg IL-1Ra in db/db mice (n=4 and 5, respectively). *P < 0.05, **P < 0.01. Statistical 547 
significance (P) was determined by Student's t test and in (a-c) by ANOVA. All error bars 548 
denote s.e.m. 549 
 550 
Figure 3 551 
Acute exposure to IL-1β induces insulin secretion without changing insulin sensitivity. 552 
 (a, b) Concentrations of circulating insulin (a) and glucose (b) during an intra-peritoneal 553 
glucose tolerance test (i.p. GTT) in WT mice 18 minutes after a single injection with saline or 554 
1 μg/kg IL-1β (n=5 and 6, respectively). (c, d) Concentrations of circulating insulin (c) and 555 
glucose (d) in 6 hour fasted WT mice injected with or without 1 μg/kg IL-1β (n=8 per group). 556 
(e) Glucose infusion rate and hepatic glucose production during a hyperinsulinemic-557 
euglycemic clamp in WT mice pre-treated with 1 μg/kg IL-1β or saline (n=4 and 3, 558 
respectively). (f-i) Concentrations of insulin (f, h) and glucose (g, i) during an i.p. GTT in diet-559 
induced obese (DIO) (f, g) and db/db (h, i) mice, pre-treated with 1 μg/kg IL-1β (n=12 per 560 
group). (j) Circulating IL-1β concentration and (k) insulin (fold of basal) 18 min after an i.p. 561 
injection of 0.1 or 1 μg/kg of IL-1β into WT mice (n=9). *P < 0.05, **P < 0.01, ***P<0.001, 562 
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****P < 0.0001. Statistical significance (P) was determined by Student's t test and in (k) by 563 
ANOVA. All error bars denote s.e.m. 564 
 565 
Figure 4 566 
Systemic IL-1β potentiates glucose-induced insulin secretion via islet IL-1R1 567 
(a) Circulating insulin and (b) glucose levels during an i.p. GTT in WT and DIO mice 3 hours 568 
after a single injection of LPS (1 mg/kg) or saline (n=5 per group). (c) Circulating insulin 569 
during an i.p. GTT in WT mice 3 hours after a single injection of saline or LPS (1 mg/kg) with 570 
or without IL-1Ra (10 mg/kg; n=5 per group). (d) Il1r1 mRNA expression in FACS sorted islet 571 
cells (n=6 experiments). (e) Double immunostaining of IL-1R1 and insulin in pancreatic tissue 572 
sections of WT and Il1r1-/- mice. Scale bar, 50 μm. (f) Circulating insulin and (g) glucose 573 
during an i.p. GTT in STZ-treated mice transplanted with WT islets or Il1r1-/- islets 18 minutes 574 
after a single injection with 1 μg/kg IL-1β (n=5 and 4). *P < 0.05, **P < 0.01, ***P<0.001, 575 
****P < 0.0001. Statistical significance (P) was determined by Student's t test and in (a-d) by 576 
ANOVA. All error bars denote s.e.m. 577 
 578 
Figure 5 579 
Insulin receptor expression and activation in peritoneal macrophages 580 
(a) Relative mean fluorescence intensity (MFI) of insulin receptor (InsR) protein in different 581 
tissue resident macrophages (4 experiments, number of circles indicates number of mice per 582 
tissue). (b) Relative MFI of InsR protein in peritoneal macrophages from WT and DIO mice 583 
(n=3 mice). (c) Insr mRNA expression in naive (M0), pro-inflammatory M1 and alternative 584 
M2 polarized macrophages (n=12; 3 experiments). (d) A representative immunoblot of 585 
insulin-induced (s473) phospho-AKT in M0, M1 and M2 polarized macrophages (1 out of 3 586 
experiments). Relative phosphorylation of (e) AKT (ser473) and (f) proteins in the MAPK 587 
signaling pathway (both assayed on the same samples; n=4 experiments). Gene expression 588 
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from M0 and M1 macrophages incubated with or without 1 μg/ml insulin: (g) Slc2a1 589 
(encoding GLUT1) and (h) Hk2 (encoding hexokinase 2); data are expressed as fold change 590 
from untreated naive controls (n=9, 3 experiments). (i) Extracellular acidification rate (ECAR; 591 
mpH/min) from polarized macrophages incubated for 2 hours in the presence or absence of 592 
1 μg/ml insulin. (n=12 or 15; 3 experiments). (j) ECAR measurements from M1 polarized 593 
macrophages acutely treated with or without 1 μg/ml insulin and 10 μM LY294002 or 10 μM 594 
U0126 (vertical line indicates treatment start, n=9; 3 experiments) (k) Glucose uptake in 595 
naive macrophages (control; n=21; 3 experiments) or incubated for 3 hours with 1 μg/ml 596 
insulin alone (n=28; 3 experiments) or in combination with 1 ng/ml IL-1β (n=15; 3 597 
experiments). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance (P) 598 
was determined by ANOVA and in (b, g) by Student's t test. All error bars denote s.e.m. 599 
 600 
Figure 6 601 
Insulin stimulates IL-1β secretion of macrophages. 602 
(a) Two-hour IL-1β secretion from 2-hour polarized macrophages isolated from WT or Nlrp3-603 
/- mice incubated with or without 1 μg/ml insulin. (b-d) Two-hour IL-1β protein release from 604 
2-hour polarized M1 macrophages with or without 1 μg/ml insulin and in combination with 605 
or without (b) 10 μM LY294002 or 20 μM rapamycin (n=9-12; 3 experiments), (c) 50 μM 606 
fasentin (n=14, 3 experiments), and (d) 2-deoxyglucose (2DG) or mitoTEMPO (n=6, 3 607 
experiments): data are presented as fold stimulation from non-treated cells. (e) IL-1Ra and 608 
(f) IL-1β protein release from 16-hour polarized macrophages incubated for 12 hours with or 609 
without 1 μg/ml insulin (n=9, 3 experiments). (g) Circulating IL-1β levels in mice treated with 610 
or without 1 unit/kg insulin (15 minutes post injection; n=10). *P < 0.05, **P < 0.01, ***P < 611 
0.001. Statistical significance (P) was determined by ANOVA. All error bars denote s.e.m. 612 
 613 
 614 
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Figure 7 615 
IL-1β shifts glucose uptake to immune cells. 616 
In vitro glucose uptake in (a) macrophages incubated with or without 1 ng/ml IL-1β for 2 617 
hours (n=15 and 11, respectively; 3 experiments) and, in (b) macrophages incubated with or 618 
without 1 μg /ml IL-1Ra for 3 hours (n=10 and 14, respectively; 3 experiments). (c-g) WT 619 
mice were injected i.p. with either saline or 1 μg/kg IL-1β or 1 μg/kg insulin (n=4 per group) 620 
18 minutes prior to an injection of 10 μCi 3H labeled 2DG. Mice were sacrificed 48 minutes 621 
after the first injection followed by assessment of glucose uptake in spleen (c), circulating 622 
leukocytes (d), visceral adipose tissue (epididymal fat pads; e), adipocytes isolated from 623 
epididymal fat pads (f) and muscle (g). (h) Number of peritoneal cells and (i) ex vivo glucose 624 
uptake in macrophages from mice injected once a day for 3 days with 35 μg/kg IL-1β (n=5 625 
per group). (j) Ex vivo glucose uptake in peritoneal macrophages from mice acutely injected 626 
with saline or 10 mg/kg IL-1Ra. (k) Circulating blood glucose and insulin levels during an 627 
intra-peritoneal glucose tolerance test after treatment with 1 μg/kg IL-1β in macrophage-628 
depleted Rag2-/- mice using an injection of 10 ml/kg clodronate or PBS liposomes (PBS; n=13, 629 
clodronate; n=8). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance 630 
(P) was determined by Student's t test and in (c-g by ANOVA). All error bars denote s.e.m. 631 
632 
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Online methods 633 
 634 
Human pancreatic islets 635 
Human islets were isolated in the islet transplantation centres of Lille and Geneva from 636 
pancreata of cadaver organ donors in accordance with the local Institutional Ethical 637 
Committee. They were obtained via the “islet for research distribution program” through 638 
the European Consortium for Islet Transplantation, under the supervision of the Juvenile 639 
Diabetes Research Foundation (31-2008-416). Islets were cultured in CMRL-1066 medium 640 
containing 5 mmol/l glucose, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM 641 
Glutamax and 10 % FCS (Invitrogen) on extracellular matrix-coated 24-well plates (Novamed 642 
Ltd.) in humid environment containing 5 % CO2.  643 
 644 
Mouse pancreatic islets 645 
To isolate mouse islets, pancreata were perfused through the sphincter of oddi with a 646 
collagenase solution (1.4 gr/l; collagenase type 4 Worthington) and digested in the same 647 
solution at 37°C, followed by sequential filtration through 500 µm and 70 µm cell strainers 648 
(BD). Islets were handpicked and cultured on extracellular matrix-coated 24-well plates 649 
(Novamed Ltd.) in RPMI-1640 (GIBCO) containing 11.1 mM glucose, 100 units/ml penicillin, 650 
100 µg/ml streptomycin, 2 mM Glutamax, 50 µg/ml gentamycin, 10 µg/ml Fungison and 10 651 
% FCS. Islets were either collected directly for RNA isolation extraction or cultured for 36 652 
hours on extracellular matrix-coated 24-well plates for subsequent glucose-stimulated 653 
insulin secretion experiments.  654 
 655 
Glucose-stimulated insulin secretion assay in islets and ENDOC cells 656 
For glucose-stimulated insulin secretion experiments, islets or the human β-cell line ENDOC 657 
cells (kindly provided by R. Sharfmann51) were cultured for 2 days and pre-incubated for 30 658 
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minutes in modified Krebs-Ringer bicarbonate buffer (KRB; 115 mM NaCl, 4.7 mM KCl, 2.6 659 
mM CaCl2 2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4 2H2O, 10 mM HEPES, 0.5 % bovine serum 660 
albumin, pH 7.4) containing 2.8 mM glucose. KRB was then replaced by KRB with 2.8 mM 661 
glucose and collected after 1 hour to determine the basal insulin release. IL-1β was added at 662 
the indicated concentrations for the last 30 minutes of the 1-hour period of the basal insulin 663 
release (priming). This was followed by 1 hour in KRB with 16.7 mM glucose to determine 664 
the stimulated insulin release. The stimulatory index was defined as the ratio of insulin 665 
secretion at 16.7 mM to 2.8 mM glucose/hour and expressed as percentage of untreated 666 
control. 667 
 668 
Animal experiments 669 
All animal experiments were performed in mice on a C57BL/6N background unless otherwise 670 
specified. Normal mice were obtained from Charles River. For the diet induced obesity (DIO) 671 
experiments, 4 week old mice were fed a high fat diet (D12331, Research Diets; containing 672 
58, 26 and 16 % calories from fat, carbohydrate and protein, respectively) for 20-25 weeks. 673 
Leptin receptor deficient (db/db) mice were obtained from Jackson laboratories at the age 674 
of 4 weeks and housed until the age of 16 weeks. Irak4-/- mice on a Balb/c background were 675 
kindly provided by Amgen. IL1b-/- mice mouse strains on a C57BL/6N background produced 676 
either by gene targeting52 or with Eucomm embryonal stem cells were used. To generate the 677 
macrophage specific IL-1β knock-out mouse (Il1bfl/flLyz2-Cre+/-) chimeric mice were produced 678 
from ES cells containing a modified Il1b allele, which contains loxP sites flanking exons 4 and 679 
5 and a frt-LacZ-loxP-neo-Frt cassette introduced between exon 3 and 4 (Eucomm clone 680 
HEPD0840_C04). Chimeric mice were then crossed with C57BL6/N mice and the offspring 681 
with germ line transmission of the recombined allele were crossed with Flp deleter mice53 682 
on Bl6/N background to excise the FRT flanked lacZ neo cassette and to obtain the Il1bfl/fl 683 
mouse. These mice were next crossed with Lyz2-Cre mice54, that were previously 684 
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backcrossed to a C57BL6/N background. As littermate control mice we used the cre 685 
recombinase negative Il1bfl/flLyz2-Cre-/- mice, and as myeloid cells specific Il1b-/- knock-out 686 
mice the Il1bfl/flLyz2-Cre+/- mice (Supplementary Fig. 1c). Nlrp3-/- mice were generated as 687 
described previously55. Rag2-/- mice were bred in house. Il1r1-/- mice and immunodeficient 688 
female swiss nude were obtained from Charles River laboratories. Glpr-/-/Grp-/- mice were 689 
generated as described56. 690 
 691 
All animal experiments were conducted according to the Swiss Veterinary Law and 692 
Institutional Guidelines and were approved by the Swiss Authorities. All animals were 693 
housed in a temperature-controlled room with a 12 h light – 12 h dark cycle and had free 694 
access to food and water.  695 
 696 
All metabolic experiments using transgenic mice were performed with wild-type littermates 697 
as controls. The mice were between 12 and 29 weeks of age. Mice that did not gain weight 698 
in diet-induced obesity experiments were excluded. All experiments were performed at least 699 
twice with weight-matched mice and with at least a total of 4 animals per group. For drug 700 
applications (apart from antibiotics treated mice that can receive commensal bacteria from 701 
non treated controls) each cage included mice receiving all treatments in order to avoid cage 702 
dependent differences. 703 
 704 
In vivo treatment administration 705 
Recombinant mouse IL-1β (R&D) was injected i.p. at the indicated time and dose. 706 
IL-1Ra (Anakinra; 10 mg/kg body weight) was injected i.p. 3 hours prior to intervention. 2-707 
deoxyglucose (1 g per kg body weight) was injected i.p 1 hour prior to refeeding. 708 
Canagliflozin (100 mg per kg body weight) or placebo control were homogenised and orally 709 
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administered 1 hour prior to refeeding. LPS (InvivoGen; 1 mg/kg body weight) was injected 710 
i.p. at the indicated time. 711 
 712 
Glucose tolerance tests (GTTs) 713 
For glucose tolerance testing, mice were fasted for 6 hours starting in the morning and 2 g 714 
glucose per kg body weight was injected i.p. Blood glucose was measured using a 715 
glucometer (Freestyle; Abbott Diabetes Care Inc.).  716 
 717 
Urine glucose levels 718 
Glycosuria was assessed according to manufacturer’s instructions (Accu Check Diabur test 719 
strips, Roche)  720 
 721 
Fasting and refeeding experiments 722 
Before blood collection, fasted mice were provided free access to water but not to food for 723 
12 hours. Refed mice were treated in the same manner as the fasted mice; however, prior to 724 
blood collection, refed mice had access to food for 2 hours. In experiments done with 725 
antibiotics or with IL-1Ra injection or with IL1b-/- mice and littermate wild-type mice, blood 726 
was collected immediately before refeeding (time 0) and 2 hours after feeding. To avoid 727 
potential confounding effects due to circadian-mediated fluctuation in circulating IL-1β 728 
levels all experiments were performed at the same time of the day (between 8 to 10 am). 729 
 730 
Glucose clamp studies 731 
Glucose clamp studies were performed in freely moving mice as previously described57. 732 
Steady state glucose infusion rate was calculated once glucose infusion reached a constant 733 
rate with blood glucose levels at 5 mmol/l (70-80 minutes after the start of insulin infusion). 734 
Thereafter, blood glucose concentration was kept constant at 5 mmol/l for 15-20 minutes 735 
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and glucose infusion rate was calculated. Glucose disposal rate, and hepatic glucose 736 
production were calculated as previously described57. 737 
 738 
Antibiotics treatment 739 
One week before fasting-refeeding experiment, 1 g/l antibiotic concoction consisting of 740 
vancomycin 10 mg/ml, neomycin 20 mg/ml, metronidazol 20 mg/ml (all purchased from 741 
Sigma), was administered by gavage every 12 hours. Gavage volume of 5 ml/kg body weight 742 
was delivered with a stainless steel tube. Fresh antibiotics concoction was mixed every day. 743 
 744 
Streptozotocin induced β-cell death and Islet transplantation. 745 
Streptozotocin (Sigma) was dissolved in citrate buffer (pH 4.5) and was i.p. injected to 746 
immunodeficient nude mice at 240 mg/kg. Only hyperglycemic mice (i.e. blood glucose > 747 
14mM) were subjected to transplantation with 500 wild-type or Il1r1-/- mouse islets, under 748 
the kidney capsule as described in58.  749 
 750 
Macrophage ablation 751 
Clodronate or PBS liposomes (ordered from ClodronateLiposomes.org) were injected i.p. 752 
(100 μl per 10 grams bodyweight) 3 days before the start of the assays. Mice were sacrificed 753 
at the end of the procedure. To verify macrophage depletion, peritoneal cells were isolated 754 
as described above and analyzed by FACS as described below. Macrophages were defined as 755 
CD11b+ F4/80+ double positive cells. 756 
 757 
Primary cell isolation and culture 758 
Cells were isolated from male C57BL/6 mice following euthanasia in a CO2 chamber. To 759 
obtain circulating leukocytes, the heart was punctured and the collected blood was 760 
incubated briefly with red blood cells lysis buffer (154mM NH4Cl, 10mM KHCO3, 0.1mM 761 
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EDTA). To isolate macrophages, the peritoneum was infused with PBS containing 1% FBS and 762 
the lavage was filtered through 70 µm cell strainer (BD). Kupffer cells were isolated from the 763 
liver perfused with 3mL collagenase through the ductal vein followed by a 30 minute 764 
incubation step and two centrifugation steps: 50 x g for 3 minutes at 4 oC, collection of the 765 
upper phase and 350 x g for 5 minutes at 4oC. Intestinal macrophages were isolated after 766 
removal of the intestinal payer patches, cut in pieces and washed twice (20 min shaking in 767 
PBS, 5mM EDTA), followed by 30min incubation in collagenase type 4 (1.4 g/l). Cells from 768 
omental and epididymal fat pads were isolated after shaking with collagenase type 4 (1.4 769 
g/l) for 30 min at 37oC. Spleens were pushed through a 70 μm cell strainer and red cells were 770 
lysed using lysis buffer (154mM NH4CL, 10mM KHCO3, 0.1mM EDTA). For islet resident 771 
macrophages, handpicked pancreatic islets were dissociated by accutase (Biolegend, 50%, 2 772 
minutes, 37 degrees) and washed. All cells were filtered through a 70 μm cell strainer 773 
washed and resuspended in FACS buffer (PBS 0.5% BSA and 5mM EDTA). For macrophage 774 
culture, cells were allowed to adhere for at least 4 hours in 48 or 96 well plates (TPP) and 775 
non-adherent cells were washed away, naive macrophages were used for glucose uptake 776 
assays or were polarized to M1 or M2 phenotypes as follows: 2 hours (serum free) or 16 777 
hours treatment with LPS (100 ng/ml) + IFNγ (10 ng/ml) for M1 and IL-13 (10 ng/ml) + IL-4 778 
(10 ng/ml) for M2 polarization, followed by 2 or 12 hours, with or without 1 μg/ml insulin in 779 
the presence or absence of fasentin (50 μM; Sigma), 2-deoxyglucose (2DG; 10mM; Sigma), 780 
mito-TEMPO (100 μM; Sigma), LY294002 (10 μM; Sigma), U0126 (10 μM; Sigma), rapamycin 781 
(20 μM; Sigma) or followed by a 30 minute incubation with ATP (5mM; Sigma). Supernatants 782 
were collected, centrifuged (at 4oC, 2000 x g for 5 minutes) and stored at -80oC and cells 783 
were either harvested for RNA extraction (see RNA extraction and qPCR) or assayed by flow 784 
cytometer for cell survival using Annexin V apoptosis detection kit (eBioscience).  785 
 786 
RNA extraction and qPCR 787 
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Total RNA was extracted using the Nucleo Spin RNA II Kit (Machery Nagel) or using RNeasy 788 
Lipid Tissue (QIAGEN). RNA concentrations were normalized and cDNA was prepared with 789 
random hexamers (Microsynth) and Superscript II (Invitrogen) according to the instructions 790 
of the supplier. RNA expression was determined with TaqMan assays and the real time PCR 791 
system 7500 (Applied Biosystems). The following TaqMan assays were used:  792 
Mouse: Gadph: Mm99999915_g1, Actb: Mm00607939_s1, Slc2a1 (encoding GLUT1): 793 
Mm00441480_m1. Il1b: Mm0043228_m1, InsR: Mm01211875_m1, Cxcl1: 794 
Mm04207460_m1, Hk2: Mm00443395_m1, Il1a: Mm00439621_m1, Il1r1: 795 
Mm00434237_m1, Ccl2: Mm00441242_m1, Tnf: Mm00443258_m1, Il6: Mm004461920_m1. 796 
Data were normalized with the geometrical mean of Gadph and Actb for macrophage mRNA 797 
and quantified using the comparative 2-ΔΔCT method. 798 
 799 
Protein and protein-phosphorylation measurement assays 800 
Insulin concentrations were determined using human insulin ultrasensitive ELISAs 801 
(Mercodia) or mouse/rat insulin kits (Mesoscale Discovery). Mouse active GLP-1 was assayed 802 
using a Mesoscale discovery kit. Protein phosphorylation was assayed using whole cell 803 
lysates (10 μg total protein) and Mesoscale Discovery kinase phosphorylation assay kits (AKT 804 
signalling panel; K15177D and MAP kinase panel; K15101D) according to manufacturer’s 805 
instructions. Mouse cytokine concentrations were assayed using the V-plex mouse IL-1β 806 
TNFα, IL-6, and CXCL1 kit from Mesoscale Discovery with the following modifications: for 807 
circulating cytokine assay, after withdrawal, blood was incubated for 30 minutes at room 808 
temperature and sera were collected after 20 minutes of centrifugation (4oC, 2000 x g). 809 
Samples were incubated in the assay plate overnight at 4oC with gentle shaking. IL-1Ra was 810 
determined using ELISA assays (R&D).  811 
 812 
Glucose bio-distribution assay 813 
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Male C57BL/6 mice were fasted for 3 hours in the morning, i.p. injected with IL-1β (1 μg/kg 814 
body weight) or saline and 18 minutes later with 3H labeled 2-deoxy glucose (10 μCi per 815 
mouse, Perkin Elmer). After 30 minutes mice were sacrificed, quadriceps muscle, epididymal 816 
adipose tissue and spleen were weighed, washed immediately in ice cold PBS and incubated 817 
with lysis buffer (10% glycerol, 5% 2-mercaptoethanol, 2.3% SDS, 62.5mM Tris pH6.8, 6M 818 
urea) followed by sonication. Leukocytes were isolated as described above, washed twice 819 
with ice cold PBS, counted and lysed with 0.1% SDS. Triplicate samples were then measured 820 
in a beta counter. Data are presented for organs as percentage beta counts per minute per 821 
mg tissue and as beta counts per cell for Leukocytes. In experiments with refed mice, 822 
fluorescent 2-deoxyglucose (2NBDG 500nmole per mouse; Invitrogen) was i.p. injected 823 
immediately after a refeeding window. Mice were sacrificed 1 hour later, peritoneal cells 824 
were harvested and analyzed by flow cytometer (BD Acurri). 825 
 826 
In vitro glucose uptake assay 827 
For in vitro treatment, macrophages were pre-incubated for 2 hours with KRB containing 1 828 
mM glucose (as described in GSIS section) with or without the indicated treatment. To 829 
determine glucose uptake, macrophages were then incubated for 30 minutes with 0.4 nCi 3H 830 
labeled 2-deoxy glucose (Perkin Elmer), washed twice with ice cold PBS, lysed with 0.1 % SDS 831 
and transferred into scintillation fluid. 3H labeled 2-deoxy glucose uptake was measured in a 832 
beta counter. 833 
 834 
Immunoblotting 835 
We separated proteins (8-12 μg) in 4-12 % NuPAGE gels (Invitrogen), blotted them onto 836 
nitrocellulose membranes (Bio-Rad) and incubated them with antibodies against total AKT 837 
(pan AKT; #4691), pAKT (s473; #9271) and Insulin receptor β (4B8; #3025.) All antibodies 838 
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were purchased from Cell Signaling. Blots were analyzed using image lab 4.1 software (Bio-839 
Rad).  840 
 841 
Flow cytometry 842 
To obtain single cells, islets were dispersed with trypsin (Invitrogen) for 6 minutes at 37°C, 843 
washed with PBS, centrifuged at 300 x g, 5 minutes, 4oC and resuspended in FACS buffer 844 
(PBS with 0.5% BSA and 2 mM EDTA). After 15 minutes incubation with an Fc blocker (Anti-845 
mouse CD16/CD32; eBioscience 14-0161) peritoneal cells or single islet cells were stained 846 
with the appropriate antibodies for 30 minutes at 4°C in the dark. To verify the effect of the 847 
clodronate depletion, cells from Rag-/- mice were stained with anti F4/80 (clone BM8) and 848 
anti CD11b (clone M1/70). To determine the peritoneal cell composition, cells were stained 849 
with anti CD3e (clone 145-2C11), anti GR-1 (clone RB6-8C5), anti CD11b (clone M1/70), anti 850 
F4/80- (clone BM8), anti CD19 (clone RA3-6B2) and anti Siglec-F-APC (clone E50-2440). 851 
Single cells from adipose tissue, islets, Liver, small intestine, and colon were stained with 852 
CD45 (clone 30-F11) for immune cells (antibodies were purchased from eBioscience, Siglec-F 853 
was purchased from BD Pharmingen). For additional intra-cellular Insulin receptor intensity 854 
in tissue resident macrophages, cells were also incubated with intracellular fixation buffer 855 
(eBioscience) following incubation with permeabilization buffer (eBioscience) according to 856 
manufacturer’s instructions. Anti InsR β (Cell Signaling; 3025S) was added following 857 
secondary conjugated donkey anti rabbit antibody (Invitrogen). Stained cells were washed 858 
twice with FACS buffer prior to FACS acquisition. Cells were analyzed with an Accuri C6 flow 859 
cytometer or LSR-Fortessa (BD Bioscience). Dispersed islet cells were analyzed and sorted 860 
with a FACS ARIA III cell sorter (BD Biosciences) using FACS Diva software (BD Biosciences). 861 
All samples were stained with appropriate isotype control antibodies; viability staining was 862 
done using 7-AAD (Sigma) or DAPI (Biolegend). Macrophages were defined as CD11b+ F4/80+ 863 
double positive cells. Data were analyzed using Flow Jo 9.4 software (Tree Star).  864 
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 865 
Extracellular acidification measurements 866 
An XF24 or an XF96e Extracellular Flux analyzer (Seahorse Biosciences) was used to 867 
determine the bioenergetic profile of FACS sorted macrophages (F4/80 and CD11b double 868 
positive peritoneal cells). Cells were plated at a density of 500’000 or 300’000 cells per well 869 
in XF24 or XF96 plate accordingly, incubated for 4 hours and washed before being 870 
stimulated with LPS (100 ng/ml) + IFNγ (10 ng/ml) or IL-4\IL-13 (10 ng/ml) for the indicated 871 
times. Insulin was injected or added to the media (1 μg/ml end concentration) for the 872 
indicated time. Prior to the assay, cells were incubated in unbuffered RPMI (Seahorse 873 
Biosciences) containing 11.1 mM glucose for 1 hour. Then extracellular acidification rate 874 
were assessed during 2 minutes. Basal measurements were followed by measurements 875 
upon injection of the following agents: Glucose (26.8 mM), oligomycin (1 μM), 876 
carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP) (2 μM), rotenone (1 μM), and 2-877 
deoxyglucose (2DG; 10mM). To activate cells with insulin during Seahorse measurments cells 878 
were incubated in unbuffered RPMI containing 5mM glucose for 1 hour, then extracellular 879 
acidification rate were assessed during 2 minutes for 6 basal measurements followed by 880 
injections of inhibitors (LY294002, 10 μM; U0126, 10 μM) or DMSO as control and insulin (1 881 
μg/ml). Oligomycin, FCCP, and rotenone were purchased from Sigma. 882 
 883 
Immunofluorescence staining 884 
Pancreata were fixed overnight in 4% paraformaldehyde at 4oC, followed by paraffin 885 
embedding. Sections were deparaffinized, re-hydrated and incubated 1 hour at room 886 
temperature with guinea pig anti-insulin antibody (Dako; A0564), followed by detection with 887 
a fluorescein-conjugated donkey anti-guinea pig antibody (Dako). Subsequently, the sections 888 
were labeled for IL-1R1 with goat anti IL-1-R1 antibody (R&D; AF771), followed by detection 889 
with a fluorescein-conjugated donkey anti-goat antibody (Invitrogen).  890 
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 891 
Statistics 892 
Appropriate statistical tests were performed where required. Comparisons between groups 893 
were performed using unpaired, two-sided t-test for normally distributed data. For grouped 894 
comparisons, one-way ANOVA or two-way ANOVA followed by Sidak's multiple comparisons 895 
analysis were used where appropriate. Statistically significant outliers were assessed using 896 
ROUT's test (O = 1%) and were excluded from analysis. Data analysis was performed using 897 
GraphPad Prism v7.0a Software Excluding diet induced obesity experiments, all animal 898 
studies were performed on weight matched mice. There was no other prior randomization 899 
or blinding. Data are expressed as means ± s.e.m. and statistical significance is denoted as *P 900 
< 0.05, **P < 0.01, ***P < 0.001 and, ****P < 0.0001. n numbers indicate biological 901 
replicates for in vitro experiments or number of mice for in vivo experiments. 902 
 903 
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